Antimicrobial Development Declines: Superbug Threat & Pediatric Access Gaps

The fight against antibiotic resistance is faltering, with pharmaceutical companies significantly scaling back their efforts to develop recent treatments for increasingly common “superbugs.” A recent analysis reveals a 35% drop in potential antimicrobial treatments in development by the world’s largest pharmaceutical firms over the past five years – from 92 projects to just 60. This decline raises serious concerns about our ability to combat infections that are becoming resistant to existing drugs, threatening to reverse decades of medical progress.

Antimicrobial resistance (AMR) occurs when microorganisms like bacteria, viruses, fungi and parasites evolve to withstand the drugs designed to kill them. This makes infections harder to treat and increases the risk of disease spread, severe illness, and death. The World Health Organization (WHO) considers AMR one of the top 10 global public health threats. WHO fact sheets on AMR detail the scope of the problem and ongoing efforts to address it.

Uneven Progress in Pediatric Formulations

The dwindling pipeline isn’t the only cause for concern. Access to new antimicrobials, when they do emerge, is as well proving uneven. Only five, or 13%, of the 39 antimicrobial pipeline projects targeting priority pathogens identified by the WHO are currently being developed with children under five in mind. While these five treatments are already approved for adult use, securing approval for pediatric populations often takes years, and in two cases, the process is still ongoing. This delay leaves a vulnerable population at increased risk.

The disparities extend geographically. In 17 sub-Saharan African countries, none of the companies assessed had registered pediatric formulations of their antimicrobials. What we have is despite the fact that these same companies did register other medicines in 10 of those countries, highlighting a clear prioritization gap. Regulatory hurdles undoubtedly exist, but the analysis suggests a lack of commercial incentive may also be a factor.

The Economic Challenge of Antibiotic Development

The decline in antimicrobial research and development is largely attributed to economic disincentives. Unlike drugs for chronic conditions, antibiotics are typically used for a short duration, resulting in lower revenue potential for pharmaceutical companies. Developing new antibiotics is also a costly and complex process, with a high failure rate. GlobalRPH’s coverage of new therapies highlights the financial challenges and the need for innovative funding models.

This economic reality creates a market failure, where the societal benefits of new antibiotics – preventing widespread infections and saving lives – are not adequately reflected in the financial returns for drug developers. The result is a shrinking pipeline and a growing threat from antibiotic-resistant infections.

The Rising Toll of Drug-Resistant Infections

The consequences of inaction are stark. Antibiotic-resistant bacterial infections already claim more than one million lives worldwide annually. Projections indicate this number will rise dramatically, with an estimated 39 million deaths attributable to antibiotic-resistant infections between 2022 and 2050 – a 69.6% increase from 2022. While deaths due to AMR are expected to decrease among young children, they are projected to increase by over 80% for adults aged 70 and above, underscoring the disproportionate impact on older populations. Research published in Frontiers in Microbiology emphasizes the growing public health threat posed by multidrug-resistant pathogens.

It’s important to note that these are projections, and the actual number of deaths will depend on a variety of factors, including the implementation of effective infection prevention and control measures, the development of new diagnostics and treatments, and global efforts to promote responsible antibiotic use.

Vaccines: A Preventative Strategy

While the development of new antibiotics is crucial, prevention is equally important. The WHO recently emphasized the potential of vaccines to reduce the burden of antimicrobial resistance. A new report from the organization suggests that increased investment in vaccines could prevent deaths due to AMR and reduce antibiotic use by 2.5 billion doses annually. Vaccines prevent infections in the first place, thereby reducing the need for antibiotics and slowing the emergence and spread of drug-resistant pathogens. The UN News report on WHO’s findings details the potential impact of expanded vaccine coverage.

The report specifically highlights the potential of vaccines against 24 pathogens to reduce antibiotic use by 22%, or 2.5 billion defined daily doses globally each year. While some of these vaccines are already available, they are often underutilized. Others require further development and rapid deployment.

What Comes Next: A Multifaceted Approach

Addressing the crisis of antibiotic resistance requires a multifaceted approach involving governments, pharmaceutical companies, healthcare providers, and the public. This includes incentivizing antibiotic research and development, promoting responsible antibiotic use, strengthening infection prevention and control measures, and investing in the development and deployment of new diagnostics and vaccines.

Several initiatives are underway to address these challenges. The WHO is working to coordinate global efforts to combat AMR, and governments around the world are implementing national action plans. Pharmaceutical companies are exploring new business models to incentivize antibiotic development, such as subscription-based payment systems.

Ongoing surveillance of antimicrobial resistance patterns is also critical. This involves monitoring the emergence and spread of resistant bacteria, tracking antibiotic use, and identifying areas where interventions are needed. Continued research into novel therapeutic approaches, such as phage therapy and immunotherapy, is also essential. The path forward demands sustained commitment and collaboration to safeguard the effectiveness of these life-saving medications for future generations.